''Minimizing Tacrolimus'' Strategy and Long-term Survival After Liver Transplantation

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2014 Aug 30

PMID 25170223

Citations 17

Authors

Jun-Jun Jia

Bin-Yi Lin

Jiang-Juan He

Lei Geng

Dhruba Kadel

Li Wang

Dong-Dong Yu

Tian Shen

Zhe Yang

Yu-Fu Ye

Lin Zhou

Shu-Sen Zheng

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the effect of the ''minimizing tacrolimus'' strategy on long-term survival of patients after liver transplantation (LT).

Methods: We conducted a retrospective study of 319 patients who received LT between January 2009 and December 2011 at the First Affiliated Hospital of Zhejiang University School of Medicine. Following elimination of ineligible patients, 235 patients were included in the study. The relationship between early tacrolimus (TAC) exposure and survival period was analyzed by Kaplan Meier curves. Adverse effects related to TAC were evaluated by the χ(2) test. Routine monitoring of blood TAC concentration (TC) was performed using the PRO-Trac(TM) II Tacrolimus Elisa Kit (Diasorin, United States).

Results: Of 235 subjects enrolled in the study, 124 (52.8%) experienced adverse effects due to TAC. When evaluating mean TC, the survival time of patients with a mean TC < 5 ng/mL was significantly shorter than that in the other groups (911.3 ± 131.6 d vs 1381.1 ± 66.1 d, 911.3 ± 131.6 d vs 1327.3 ± 47.8 d, 911.3 ± 131.6 d vs 1343.2 ± 83.1 d, P < 0.05), while the survival times of patients with a mean TC of 5-7, 7-10 and 10-15 ng/mL were comparable. Adverse effects due to TAC in all four groups were not significantly different. When comparing the standard deviation (SD) of TC among the groups, the survival time of patients with a SD of 2-4 was significantly longer than that in the other groups (1388.8 ± 45.4 d vs 1029.6 ± 131.3 d, 1388.8 ± 45.4 d vs 1274.9 ± 57.0 d, P < 0.05), while in patients with a SD < 2 and SD > 4, the survival time was not statistically different. Adverse effects experienced in all three groups were not statistically different. In Cox regression analysis, male patients and those with a primary diagnosis of benign disease, mean TC > 5 ng/mL and TC SD 2-4 had better outcomes.

Conclusion: The early ''minimizing tacrolimus'' strategy with a mean TC of 5-10 ng/mL and SD of 2-4 was beneficial in terms of long-term survival after LT.

Citing Articles

Evaluation of Humoral Response following SARS-CoV-2 mRNA-Based Vaccination in Liver Transplant Recipients Receiving Tailored Immunosuppressive Therapy.

Manzia T, Sensi B, Conte L, Siragusa L, Angelico R, Frongillo F J Clin Med. 2023; 12(21).

PMID: 37959382 PMC: 10650358. DOI: 10.3390/jcm12216913.

The impact of acute kidney injury with or without recovery on long-term kidney outcome in patients undergoing living liver transplantation.

Chiu P, Lin P, Tsai C, Hsieh Y Nephrol Dial Transplant. 2023; 38(8):1817-1822.

PMID: 36651817 PMC: 10387382. DOI: 10.1093/ndt/gfad005.

Genotype-guided model significantly improves accuracy of tacrolimus initial dosing after liver transplantation.

Shi B, Liu Y, Liu D, Yuan L, Guo W, Wen P EClinicalMedicine. 2022; 55:101752.

PMID: 36444212 PMC: 9700266. DOI: 10.1016/j.eclinm.2022.101752.

New-Onset Diabetes Mellitus (NODM) After Liver Transplantation (LT): The Ultimate Non-diabetogenic Immunosuppressive Therapy.

Chaitou A, Valmiki S, Valmiki M, Zahid M, Aid M, Fawzy P Cureus. 2022; 14(3):e23635.

PMID: 35510006 PMC: 9057316. DOI: 10.7759/cureus.23635.

Long-Term Follow-Up of Renal Function in Children after Liver Transplantation-A Single Center Retrospective Study.

Kowalewski G, Kalicinski P, Stefanowicz M, Grenda R, Czubkowski P, Szymczak M Children (Basel). 2021; 8(8).

PMID: 34438524 PMC: 8391198. DOI: 10.3390/children8080633.

References

Rodriguez-Peralvarez M, Germani G, Papastergiou V, Tsochatzis E, Thalassinos E, Luong T . Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome. J Hepatol. 2012; 58(2):262-70. DOI: 10.1016/j.jhep.2012.09.019. View

Varo Perez E, Castroagudin J . The future of liver transplantation. Transplant Proc. 2010; 42(2):613-6. DOI: 10.1016/j.transproceed.2010.02.003. View

Ansermot N, Fathi M, Veuthey J, Desmeules J, Hochstrasser D, Rudaz S . Quantification of cyclosporine A in peripheral blood mononuclear cells by liquid chromatography-electrospray mass spectrometry using a column-switching approach. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 857(1):92-9. DOI: 10.1016/j.jchromb.2007.07.001. View

Starzl T, Todo S, Fung J, Demetris A, Venkataramman R, Jain A . FK 506 for liver, kidney, and pancreas transplantation. Lancet. 1989; 2(8670):1000-4. PMC: 2966318. DOI: 10.1016/s0140-6736(89)91014-3. View

Zahir H, McCaughan G, Gleeson M, Nand R, McLachlan A . Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol. 2004; 57(3):298-309. PMC: 1884454. DOI: 10.1046/j.1365-2125.2003.02008.x. View

Barbier L, Garcia S, Cros J, Borentain P, Botta-Fridlund D, Paradis V . Assessment of chronic rejection in liver graft recipients receiving immunosuppression with low-dose calcineurin inhibitors. J Hepatol. 2013; 59(6):1223-30. DOI: 10.1016/j.jhep.2013.07.032. View

Trunecka P, Boillot O, Seehofer D, Pinna A, Fischer L, Ericzon B . Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. Am J Transplant. 2010; 10(10):2313-23. DOI: 10.1111/j.1600-6143.2010.03255.x. View

OGrady J, Hardy P, Burroughs A, Elbourne D . Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transplant. 2006; 7(1):137-41. DOI: 10.1111/j.1600-6143.2006.01576.x. View

Ojo A, Held P, Port F, Wolfe R, Leichtman A, Young E . Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003; 349(10):931-40. DOI: 10.1056/NEJMoa021744. View

10.

Koesukwiwat U, Jayanta S, Leepipatpiboon N . Validation of a liquid chromatography-mass spectrometry multi-residue method for the simultaneous determination of sulfonamides, tetracyclines, and pyrimethamine in milk. J Chromatogr A. 2006; 1140(1-2):147-56. DOI: 10.1016/j.chroma.2006.11.099. View

11.

Rodriguez-Peralvarez M, Tsochatzis E, Naveas M, Pieri G, Garcia-Caparros C, OBeirne J . Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol. 2013; 59(6):1193-9. DOI: 10.1016/j.jhep.2013.07.012. View

12.

Boillot O, Seket B, Dumortier J, Pittau G, Boucaud C, Bouffard Y . Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study. Liver Transpl. 2009; 15(11):1426-34. DOI: 10.1002/lt.21905. View

13.

Capron A, Lerut J, Latinne D, Rahier J, Haufroid V, Wallemacq P . Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study. Transpl Int. 2011; 25(1):41-7. DOI: 10.1111/j.1432-2277.2011.01365.x. View

14.

Venkataramanan R, Shaw L, Sarkozi L, Mullins R, Pirsch J, Macfarlane G . Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol. 2001; 41(5):542-51. DOI: 10.1177/00912700122010429. View

15.

Rodriguez-Peralvarez M, Germani G, Darius T, Lerut J, Tsochatzis E, Burroughs A . Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. Am J Transplant. 2012; 12(10):2797-814. DOI: 10.1111/j.1600-6143.2012.04140.x. View

16.

Kershner R, Fitzsimmons W . Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation. 1996; 62(7):920-6. DOI: 10.1097/00007890-199610150-00009. View

17.

Crettol S, Venetz J, Fontana M, Aubert J, Ansermot N, Fathi M . Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genomics. 2008; 18(4):307-15. DOI: 10.1097/FPC.0b013e3282f7046f. View

18.

Karie-Guigues S, Janus N, Saliba F, Dumortier J, Duvoux C, Calmus Y . Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study. Liver Transpl. 2009; 15(9):1083-91. DOI: 10.1002/lt.21803. View

19.

Calmus Y, Kamar N, Gugenheim J, Duvoux C, Ducerf C, Wolf P . Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. Transplantation. 2010; 89(12):1504-10. DOI: 10.1097/TP.0b013e3181db8cf0. View

20.

Boudjema K, Camus C, Saliba F, Calmus Y, Salame E, Pageaux G . Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant. 2011; 11(5):965-76. DOI: 10.1111/j.1600-6143.2011.03486.x. View